Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Atom Bioworks
AddedFeb 15, 2024
UpdatedJun 18, 2026
Atom Bioworks

Atom Bioworks

Pre-Seed

Atom Bioworks: A startup specializing in DNA nanostructures for medical platforms.

HQ
Cary, NC, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Atom Bioworks specializes in DNA nanostructures designed for medical platforms, focusing on enabling targeted drug delivery. The company's core mission is to develop rationally designed DNA-based materials that can target previously untargetable areas, enhancing the precision and efficacy of medical treatments. Atom Bioworks aims to revolutionize the field of drug delivery by leveraging advanced DNA nanotechnology.

The company has made significant strides in the biotechnology sector, contributing to the development of innovative solutions for targeted drug delivery. By focusing on DNA nanostructures, Atom Bioworks has positioned itself as a leader in the niche market of precision medicine. Their work has the potential to significantly impact patient outcomes by providing more effective and targeted treatment options.

Atom Bioworks - Similar Companies

Atomic AI logo

Atomic AI

atomic.ai

Aptabridge logo

Aptabridge

aptabridge.com

Atommap logo

Atommap

Nano RED logo

Nano RED

Optimeos Life Sciences logo

Optimeos Life Sciences

optimeos.com

Lattice Therapeutics logo

Lattice Therapeutics

Atavistik Bio logo

Atavistik Bio

atavistikbio.com

BioDatomics logo

BioDatomics

biodatomics.com

Mana.bio logo

Mana.bio

mana.bio

Alltrna logo

Alltrna

alltrna.com

Cytonus Therapeutics logo

Cytonus Therapeutics

cytonus.com

Twist Bioscience logo

Twist Bioscience

Advanced NanoTherapies logo

Advanced NanoTherapies

Dnalite Therapeutics logo

Dnalite Therapeutics

Nanotransfer logo

Nanotransfer

nanotransfer.bio

Atom Bioworks - Quick Facts

Who are Atom Bioworks' competitors?

Companies similar to Atom Bioworks include Atomic AI, Aptabridge, Atommap and Nano RED.

When was Atom Bioworks founded?

Atom Bioworks was founded in 2020.

Where is Atom Bioworks' headquarters located?

Atom Bioworks' headquarters is located in Cary, NC, US.

When was Atom Bioworks' last funding round?

Atom Bioworks' most recent funding round was for $998.5k (USD) in July 2022.

How much has Atom Bioworks raised to-date?

As of Jul 20, 2022, Atom Bioworks has raised a total of $6.5M (USD).

How many employees does Atom Bioworks have?

Atom Bioworks has 9 employees as of Feb 4, 2024.

Atom Bioworks - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Americas
Model
  • Platform
Customer
  • Enterprise
  • Government
Main Product
  • Drug Delivery
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software